














Heart failure is a major killer, aﬀecting well over a million people in the UK alone. We
now have over 20 years' worth of evidence from clinical trials that show strong beneﬁts
for a package of treatment involving not only drugs and devices but also where patients
stay, how they are cared for and how the diﬀerent healthcare professionals work with
one another. Yet in many cases, doctors are not acting on the ﬁndings.
This is just one example of a major problem in healthcare across the world. Billions of
pounds are spent each year researching clinical treatments, but a staggering 85% of all 
research ends up not being put into practice – much of it passed over for reasons that
could be avoided. Even when research ﬁndings are taken up by clinicians and those in
charge of health policy, the average delay between publication and practice is 17 years.
The more medical conditions you consider, the more examples crop up. Research into
a new care package for chronic kidney disease was shown to be eﬀective, for example,
but it is not implemented by GPs because they are struggling to prioritise it over other




Or take Bell’s palsy, a condition where muscle weaknesses cause a suﬀerer’s facial
features to droop on one side. Many patients are not being given the treatment shown
in trials to be the most eﬀective. In lung cancer of the non-small cells, meanwhile, a new
radiotherapy treatment has been proven to be a better cure than conventional
radiotherapy. Yet it is not widely given because of doctors' preferences and the
practicalities of providing it in hospitals.
Trials and context
So what’s the problem? This gap between evidence and practice has produced a whole
ﬁeld of research in its own right called implementation science or knowledge transfer,
which has identiﬁed various issues. Some trials are not of high enough quality. This can
be for any number of reasons including problems with the way participants are
selected, conducting the wrong trials or conducting the right trials the wrong way.
Other trials are not published because they did not produce a result in favour of the
new treatment being tested. Initiatives such as the All Trials campaign aim to get all
trials registered and their results published so that we can see the full picture, not a
distorted one.
Yet this won’t solve everything. This is because one of the biggest problems, which has
perhaps not received enough attention in the past, is that research ﬁndings are
frequently much less meaningful to clinicians and policymakers in the real world than
they could be.
Trials don’t collect suﬃcient information about the context in which they were
conducted, or about how contextual factors aﬀected the results. So outside the direct
trial setting, the results can either be less useful or it can be hard to judge whether they
will be useful or not.
Even a seemingly simple switch from one pill to another can
stumble because of things like its cost and availability, patient
preferences, or beliefs among staﬀ as to the beneﬁts of the old
drug. And when it comes to complex team-delivered
treatments such as surgery or rehabilitation, the scope for
context to matter increases enormously.
The need to look closer
Many specialists believe the answer is to run separate studies
alongside clinical trials that aim to understand their context,
their processes and all the relevant variables that come into
play. These are expensive, though not prohibitively so, and 
work is going on into how to make them cheaper. The UK
Medical Research Council last year published guidance on how
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One thing lacking from this guidance, however, was much
explanation of how context should be explored in these studies. This is because we’ve
yet to fully understand the problem. An overview of 70 reviews looking at why GPs and
other professionals in primary care don’t put research ﬁndings into practice recently
concluded that future research needs to concentrate on how and why contextual factors
play a part.
There also appears to be another obstacle. There is growing pressure to prioritise
funding for research that has the greatest impact on clinical care. Methodology research
into the context problem doesn’t have an immediate impact on clinical care, which
makes it harder to attract funding. It currently attracts only a small part of the overall 
budget for healthcare research.
The paradox is that until we properly understand how context inﬂuences trials, their
results will continue failing to achieve their potential impact on clinical care. In other
words, 85% of research will continue to be wasted. When the alternative is that millions
of people do not get the best treatment available, the only logical move is to make this a
top priority.
GP’s perspective still poorly understood. Nonwarit
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